Dexamethasone Intravitreal Implant in Combination with Laser Photocoagulation for the Treatment of Diffuse Diabetic Macular Edema

Texas Retina Associates, Arlington, Texas. Electronic address: .
Ophthalmology (Impact Factor: 5.56). 05/2013; 120(9). DOI: 10.1016/j.ophtha.2013.02.018
Source: PubMed

ABSTRACT PURPOSE: To evaluate Ozurdex (dexamethasone intravitreal implant [DEX implant]; Allergan, Inc, Irvine, CA) 0.7 mg combined with laser photocoagulation compared with laser alone for treatment of diffuse diabetic macular edema (DME). DESIGN: Randomized, controlled, multicenter, double-masked, parallel-group, 12-month trial. PARTICIPANTS: Two hundred fifty-three patients with retinal thickening and impaired vision resulting from diffuse DME in at least 1 eye (the study eye) were enrolled. INTERVENTION: Patients were randomized to treatment in the study eye with DEX implant at baseline plus laser at month 1 (combination treatment; n = 126) or sham implant at baseline and laser at month 1 (laser alone; n = 127) and could receive up to 3 additional laser treatments and 1 additional DEX implant or sham treatment as needed. MAIN OUTCOME MEASURES: The primary efficacy variable was the percentage of patients who had a 10-letter or more improvement in best-corrected visual acuity (BCVA) from baseline at month 12. Other key efficacy variables included the change in BCVA from baseline and the area of vessel leakage evaluated with fluorescein angiography. Safety variables included adverse events and intraocular pressure (IOP). RESULTS: The percentage of patients who gained 10 letters or more in BCVA at month 12 did not differ between treatment groups, but the percentage of patients was significantly greater in the combination group at month 1 (P<0.001) and month 9 (P = 0.007). In patients with angiographically verified diffuse DME, the mean improvement in BCVA was significantly greater with DEX implant plus laser treatment than with laser treatment alone (up to 7.9 vs. 2.3 letters) at all time points through month 9 (P≤0.013). Decreases in the area of diffuse vascular leakage measured angiographically were significantly larger with DEX implant plus laser treatment through month 12 (P≤0.041). Increased IOP was more common with combination treatment. No surgeries for elevated IOP were required. CONCLUSIONS: There was no significant between-group difference at month 12. However, significantly greater improvement in BCVA, as demonstrated by changes from baseline at various time points up to 9 months and across time based on the area under the curve analysis, occurred in patients with diffuse DME treated with DEX implant plus laser than in patients treated with laser alone. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Our objective was to investigate the efficacy and safety of dexa methasone (DEX) implant for the treatment of pseudophakic cystoid macular edema (PCME) in diabetic patients.
    Drug Design, Development and Therapy 01/2014; 8:1441-1449. DOI:10.2147/DDDT.S66611 · 3.03 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review To review the current management and recent changes in treatment paradigm for diabetic macular edema (DME). Recent findings During the review period (1 year), several prospective studies analyzed the beneficial effect of anti-vascular endothelial growth factor agents in the management of DME. An exploratory analysis concluded that intravitreal ranibizumab appears to be associated with a reduced risk of diabetic retinopathy worsening. A randomized, controlled, multicenter, double-masked, parallel-group, 12-month trial to evaluate a dexamethasone intravitreal implant (DEX implant) combined with laser photocoagulation compared with laser alone for treatment of DME concluded that there was no significant between-group difference at month 12. A multicenter, prospective, observational study found that in eyes with diabetic retinopathy without concurrent central-involved DME, presence of noncentral-involved DME immediately prior to cataract surgery or history of DME treatment may increase the risk of developing central-involved macular edema after cataract extraction. Another randomized trial to evaluate whether intravitreal ranibizumab injection at cataract surgery prevents postoperative DME concluded that intravitreal ranibizumab injection at cataract surgery may prevent the postoperative worsening of macular edema. Summary The results of clinical trials have shown the superiority of some of these anti-vascular endothelial growth factor agents to laser therapy. However, with the availability of several of these newer agents, it may be difficult to individualize treatment options, especially if DME patients respond differently to various therapies.
    Current Opinion in Ophthalmology 09/2014; 25(6). DOI:10.1097/ICU.0000000000000102 · 2.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diabetic macular edema is considered the most important factor related to visual impairment in patients with diabetic retinopathy. Together with the use of grid and focal laser photocoagulation, today the intravitreal administration of pharmacotherapies represents the standard of care for the treatment of this complication: anti-vascular endothelium growth factor agents and steroids are the drugs currently used for this aim. Differently from laser therapy, which prevents visual deterioration, the intravitreal approach allows the promotion of visual recovery. However, the intravitreal injections require to be repeated with high frequency, and this carries the risk of drug- and procedure-related adverse effects. © 2014 S. Karger AG, Basel.
    Ophthalmic Research 08/2014; 52(2):89-96. DOI:10.1159/000362764 · 1.56 Impact Factor